MLICM
MACK

Metropolitan Life Insurance Company (MetLife)’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-581
Closed -$8.58K – 2296
2024
Q1 		$8.58K Hold
581
– – ﹤0.01% 2183
2023
Q4 		$7.79K Hold
581
– – ﹤0.01% 2249
2023
Q3 		$7.16K Hold
581
– – ﹤0.01% 2350
2023
Q2 		$7.15K Buy
+581
New +$7.26K ﹤0.01% 2424
2017
Q2 		– Sell
-11,830
Closed -$287K – 2612
2017
Q1 		$287K Buy
11,830
+723
+7% +$18.1K ﹤0.01% 2036
2016
Q4 		$357K Sell
11,107
-723
-6% -$30.8K ﹤0.01% 1964
2016
Q3 		$591K Sell
11,830
-34
-0.3% -$1.41K ﹤0.01% 1596
2016
Q2 		$503K Buy
11,864
+337
+3% +$18.4K ﹤0.01% 1694
2016
Q1 		$759K Buy
11,527
+1,752
+18% +$91.5K 0.01% 1316
2015
Q4 		$608K Buy
9,775
+290
+3% +$20.4K ﹤0.01% 1502
2015
Q3 		$635K Sell
9,485
-356
-4% -$29.1K ﹤0.01% 1476
2015
Q2 		$957K Buy
9,841
+407
+4% +$38.7K 0.01% 1319
2015
Q1 		$882K Hold
9,434
– – 0.01% 1272
2014
Q4 		$839K Hold
9,434
– – 0.01% 1446
2014
Q3 		$652K Hold
9,434
– – ﹤0.01% 1543
2014
Q2 		$541K Hold
9,434
– – ﹤0.01% 1778
2014
Q1 		$374K Hold
9,434
– – ﹤0.01% 2006
2013
Q4 		$396K Hold
9,434
– – ﹤0.01% 1977
2013
Q3 		$282K Hold
9,434
– – ﹤0.01% 2157
2013
Q2 		$500K Buy
+9,434
New +$414K ﹤0.01% 1696

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MACK Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 581 shares — an estimated $8.58K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MACK in Q2 2013 and held it in 20 quarters. The position peaked at $957K in Q2 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 581 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $8.58K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Merrimack Pharmaceuticals, Inc. position peaked at $957K in Q2 2015.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.